The cyclin dependent kinase inhibitor Roscovitine prevents diet-induced metabolic disruption in obese mice.

ABSTRACT: Most strategies to treat obesity-related disorders have involved prevention of diet-induced weight gain in lean mice. Treatment of obese individuals will require therapies that reverse the detrimental effects of excess body weight. Cyclin-dependent kinases have been shown to contribute to obesity and its adverse complications. Here, we show that roscovitine; a an orally available cyclin-dependent kinase inhibitor; given to male mice during the last six weeks of a 19-week high fat diet, reduced weight gain and prevented accompanying insulin resistance, hepatic steatosis, visceral adipose tissue (eWAT) inflammation/fibrosis as well as restored insulin secretion and enhanced whole body energy expenditure. Proteomics and phosphoproteomics analysis of eWAT demonstrated that roscovitine suppress

SUBMITTER: Rabhi N 

PROVIDER: S-EPMC8514475 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature